GlassScriptPhysician profile
Aaron Burg
NPI 1710286984
$1,320.53
in general payments reported to CMS, 2019-2025
19 companies · $214 in 2025
The $214 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42.18 · 2020: $25.61 · 2022: $456 · 2023: $300 · 2024: $283 · 2025: $214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $797.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $797.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $267.82 | 2019-2025 | |
| Boston Scientific Corporation | $169.96 | 2019-2022 | |
| Heartflow, INC. | $127.06 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $106.55 | 2019-2023 | Brilinta |
| Amgen INC. | $92.10 | 2022-2025 | Repatha, Repatha |
| Novo Nordisk INC | $83.30 | 2023-2025 | Ozempic, Wegovy |
| E.R. Squibb & Sons, L.L.C. | $75.69 | 2022-2025 | Eliquis |
| Merck Sharp & Dohme LLC | $67.83 | 2022-2023 | Verquvo |
| Alnylam Pharmaceuticals INC. | $56.50 | 2022-2023 | Onpattro |
| Novartis Pharmaceuticals Corporation | $52.88 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $50.14 | 2022 | |
| Abbott Laboratories | $45.01 | 2022-2024 | Mitraclip |
| Sanofi-Aventis U.S. LLC | $27.87 | 2024 | |
| Lantheus Medical Imaging, INC. | $21.31 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $18.25 | 2024 | Arcalyst |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $16.69 | 2022 | |
| Altathera Pharmaceuticals LLC | $14.56 | 2022 | |
| Ge Healthcare | $14.29 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $12.72 | 2023 | Inpefa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Burg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.